Risperidone Depot (Microspheres) [Risperidone] in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-Label Follow-up Trial of RIS-INT-62 and RIS-INT-85.

Trial Profile

Risperidone Depot (Microspheres) [Risperidone] in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-Label Follow-up Trial of RIS-INT-62 and RIS-INT-85.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen
  • Most Recent Events

    • 21 May 2010 Actual patient number (314) added as reported by ClinicalTrials.gov.
    • 06 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov
    • 19 Nov 2007 Status changed from completed to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top